Rema Raman, PhD
Biography
Rema Raman is a Professor of Neurology at Keck School of Medicine of USC and the Director of Biostatistics at the USC Alzheimer’s Therapeutic Research Institute (ATRI). She is the lead of the Biostatistics Unit and the co-lead of the Recruitment Unit for the Alzheimer’s Clinical Trials Consortium (ACTC).
Dr. Raman has focused her academic career in the design, conduct and analysis of clinical trials in neurology. She has extensive experience as a collaborative biostatistician and clinical trialist, serving in the leadership team of several highly integrated and interdisciplinary research programs conducting clinical research in Alzheimer¹s disease, acute stroke, post-traumatic stress disorder, and traumatic brain injury. Her primary statistical research interests are in correlated and missing data issues, design and analysis of efficient clinical trials and cohort studies, centralized and adaptive statistical monitoring approaches, and effective safety monitoring.
Dr. Raman is deeply committed to the effective teaching of biostatistics and clinical trial methodology to medical students, graduate students, clinical fellows and other clinical researchers. She has taught clinical trials to graduate students and medical residents/fellows and Biostatistics to basic science and public health graduate students as well as medical students. She has trained physicians on biostatistics and clinical research methodology and provided the statistical mentorship to many research projects. She is co-director of the Institute of Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD), a course that aims to educate and promote diversity among research professionals and future principal investigators in the field of Alzheimer’s Disease and Related Disorders research, and the co-Chair of the ACTC Inclusion, Diversity and Education in Alzheimer’s disease Clinical Trials (IDEA-CT) committee.
Publications
Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a randomized trial Sci Rep. 2022 Jan 25; 12(1):1346.
Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial JAMA Netw Open. 2021 Jul 01; 4(7):e2114364.
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial JAMA Neurol. 2021 Mar 01; 78(3):293-301.
Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies Sleep Adv. 2021; 2(1):zpab015.
The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program J Prev Alzheimers Dis. 2021; 8(3):286-291.
Your Title Goes Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Your Title Goes Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Your Title Goes Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.